inclusion criteria: 1. the presence of a written informed consent of the subject to participate in the study; 2. adult volunteers over 18; 3. negative test result for hiv, hepatitis, syphilis; 4. negative test result for covid-2019, determined by pcr at the visit screening, and, if available, the result of the examination performed in medical organizations that are research centers 7 days before inclusion into research; 5. the result of the study for the presence of igg antibodies to sars cov2 up to 10 vgr, which corresponds to value up to 100 bau, regardless of the immune status before; 6. absence of contact of the research subject with patients with covid-2019 for at least 14 days before enrollment in the study (according to the study participant); 7. consent to use effective methods of contraception during the entire period of participation in research; 8. negative urine pregnancy test at screening visit (for women of childbearing age); 9. negative test for the presence of narcotic and psychostimulant drugs in the urine for screening visit; 10. negative alcohol test at screening visit; 11. no history of severe post-vaccination reactions or post-vaccination complications after the use of immunobiological preparations; 12. absence of acute infectious and/or respiratory diseases for at least within 14 days prior to enrollment in the study.

inclusion criteria: 1. the presence of a written informed consent of the subject to participate in the study; 2. adult volunteers over 18; 3. negative test result for hiv, hepatitis, syphilis; 4. negative test result for covid-2019, determined by pcr at the visit screening, and, if available, the result of the examination performed in medical organizations that are research centers 7 days before inclusion into research; 5. the result of the study for the presence of igg antibodies to sars cov2 up to 10 vgr, which corresponds to value up to 100 bau, regardless of the immune status before; 6. absence of contact of the research subject with patients with covid-2019 for at least 14 days before enrollment in the study (according to the study participant); 7. consent to use effective methods of contraception during the entire period of participation in research; 8. negative urine pregnancy test at screening visit (for women of childbearing age); 9. negative test for the presence of narcotic and psychostimulant drugs in the urine for screening visit; 10. negative alcohol test at screening visit; 11. no history of severe post-vaccination reactions or post-vaccination complications after the use of immunobiological preparations; 12. absence of acute infectious and/or respiratory diseases for at least within 14 days prior to enrollment in the study.

inclusion criteria: the presence of a written informed consent of the subject to participate in the study; adult volunteers over 18; negative test result for hiv, hepatitis, syphilis; negative test result for covid-2019, determined by pcr at the visit screening, and, if available, the result of the examination performed in medical organizations that are research centers 7 days before inclusion into research; the result of the study for the presence of igg antibodies to sars cov2 up to 10 vgr, which corresponds to value up to 100 bau, regardless of the immune status before; absence of contact of the research subject with patients with covid-2019 for at least 14 days before enrollment in the study (according to the study participant); consent to use effective methods of contraception during the entire period of participation in research; negative urine pregnancy test at screening visit (for women of childbearing age); negative test for the presence of narcotic and psychostimulant drugs in the urine for screening visit; negative alcohol test at screening visit; no history of severe post-vaccination reactions or post-vaccination complications after the use of immunobiological preparations; absence of acute infectious and/or respiratory diseases for at least within 14 days prior to enrollment in the study.

inclusion criteria: the presence of a written informed consent of the subject to participate in the study; adult volunteers over 18; negative test result for hiv, hepatitis, syphilis; negative test result for covid-2019, determined by pcr at the visit screening, and, if available, the result of the examination performed in medical organizations that are research centers 7 days before inclusion into research; the result of the study for the presence of igg antibodies to sars cov2 up to 10 vgr, which corresponds to value up to 100 bau, regardless of the immune status before; absence of contact of the research subject with patients with covid-2019 for at least 14 days before enrollment in the study (according to the study participant); consent to use effective methods of contraception during the entire period of participation in research; negative urine pregnancy test at screening visit (for women of childbearing age); negative test for the presence of narcotic and psychostimulant drugs in the urine for screening visit; negative alcohol test at screening visit; no history of severe post-vaccination reactions or post-vaccination complications after the use of immunobiological preparations; absence of acute infectious and/or respiratory diseases for at least within 14 days prior to enrollment in the study.